GlassScriptPhysician profile
Matthew G Wilde
NPI 1760987036
$2,840.02
in general payments reported to CMS, 2019-2025
20 companies · $902 in 2025
The $902 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $22.98 · 2021: $37.32 · 2022: $752 · 2023: $479 · 2024: $548 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,927.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $580.35 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $508.01 | 2022-2025 | Eylea, Eylea Hd |
| Harrow Eye, LLC | $303.88 | 2024-2025 | Iheezo |
| Genentech USA, INC. | $206.55 | 2023-2025 | Susvimo, Vabysmo |
| Biogen, INC. | $170.04 | 2022-2024 | Byooviz |
| Bausch & Lomb Americas INC. | $136.94 | 2022-2023 | Stellaris |
| Abbvie INC. | $130.00 | 2024-2025 | |
| Eyepoint US, INC. | $126.49 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $116.02 | 2025 | Xdemvy |
| Astellas Pharma US INC | $111.33 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $101.63 | 2024-2025 | Syfovre |
| Allergan, INC. | $99.99 | 2019 | |
| Ani Pharmaceuticals, INC. | $58.93 | 2025 | Iluvien, Yutiq |
| Merck Sharp & Dohme LLC | $33.36 | 2025 | Keytruda |
| Neurotech Pharmaceuticals, INC. | $32.73 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $30.10 | 2025 | Stravix |
| Axogen | $25.81 | 2024 | Axoguard Nerve Cap, Axoguard Ha+ Nerve Protector, Axoguard Nerve Protector |
| Optinose US, INC. | $23.46 | 2025 | |
| Alimera Sciences, INC. | $22.58 | 2024 | Yutiq, Iluvien |
| Notal Vision, INC. | $21.82 | 2025 | Foresee Home |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Wilde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.